Sonnet biotherapeutics receives notice of allowance for u.s. patent covering composition of matter of specific amino acid substitutions of its il-18 binding protein resistant variant protein

Company advancing development of its modified version of interleukin-18 (il-18 binding protein resistant or il-18 bpr ) that exhibits wild-type binding to the il-18 receptor (il-18rc), coupled with undetectable binding to the inhibitory il-18 binding protein (il-18bp) thus making il-18 bpr more effective in vitro
SONN Ratings Summary
SONN Quant Ranking